MRKR Files 8-K on Jan 8, Signals Corporate Communications Activity
Ticker: MRKR · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1094038
| Field | Detail |
|---|---|
| Company | Marker Therapeutics, Inc. (MRKR) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-action, regulatory-filing, business-combination
TL;DR
**MRKR filed an 8-K on Jan 8, hinting at potential M&A or significant corporate comms.**
AI Summary
Marker Therapeutics, Inc. (MRKR) filed an 8-K on January 8, 2024, indicating a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. This filing is a standard procedural update, specifically noting it satisfies obligations under Rule 425 of the Securities Act, which typically relates to written communications regarding business combinations. For investors, this matters because it signals ongoing corporate activity, potentially related to a merger, acquisition, or other significant transaction that could impact the stock's future valuation and strategic direction.
Why It Matters
This filing indicates Marker Therapeutics is engaging in communications related to a potential business combination, which could lead to significant changes in the company's structure or operations, directly impacting shareholder value.
Risk Assessment
Risk Level: medium — The filing itself is procedural, but the underlying event it signals (potential business combination) carries inherent risks and opportunities for investors.
Analyst Insight
A smart investor would monitor Marker Therapeutics (MRKR) closely for subsequent filings or press releases that elaborate on the nature of the 'written communications pursuant to Rule 425,' as this often precedes significant corporate actions like mergers or acquisitions.
Key Numbers
- 001-37939 — Commission File Number (identifies Marker Therapeutics' filings with the SEC)
- 45-4497941 — IRS Employer Identification No. (identifies Marker Therapeutics for tax purposes)
- $0.001 — par value per share (the nominal value of Marker Therapeutics' common stock)
Key Players & Entities
- Marker Therapeutics, Inc. (company) — the registrant filing the 8-K
- MRKR (company) — the trading symbol for Marker Therapeutics, Inc.
- The Nasdaq Stock Market LLC (company) — the exchange where MRKR common stock is registered
- January 8, 2024 (date) — date of earliest event reported and filing date
- Delaware (company) — state of incorporation for Marker Therapeutics, Inc.
Forward-Looking Statements
- Marker Therapeutics will announce details of a business combination or significant transaction. (Marker Therapeutics, Inc.) — medium confidence, target: Q1 2024
- MRKR stock price will experience volatility following any announcement related to a business combination. (MRKR) — high confidence, target: Q1 2024
FAQ
What is the primary purpose of this 8-K filing by Marker Therapeutics, Inc.?
The primary purpose of this 8-K filing is to serve as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically indicating that it is intended to simultaneously satisfy the filing obligation of the registrant under Rule 425 under the Securities Act.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 8, 2024.
What is the trading symbol and the exchange where Marker Therapeutics, Inc.'s common stock is registered?
Marker Therapeutics, Inc.'s common stock trades under the symbol MRKR and is registered on The Nasdaq Stock Market LLC.
What is the address of Marker Therapeutics, Inc.'s principal executive offices?
The address of Marker Therapeutics, Inc.'s principal executive offices is 9350 Kirby Drive, Suite 300, Houston, Texas 77054.
What specific rule under the Securities Act is mentioned in this 8-K filing?
This 8-K filing specifically mentions satisfying the filing obligation under Rule 425 under the Securities Act (17 CFR 230.425), which relates to written communications in business combinations.
Filing Stats: 647 words · 3 min read · ~2 pages · Grade level 9.9 · Accepted 2024-01-08 08:30:48
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share MRKR The Nasdaq Stock Mar
Filing Documents
- tm242285d1_8k.htm (8-K) — 26KB
- tm242285d1_ex99-1.htm (EX-99.1) — 27KB
- tm242285d1_ex99-2.htm (EX-99.2) — 28KB
- tm242285d1_ex99-1img001.jpg (GRAPHIC) — 20KB
- tm242285d1_ex99-2img001.jpg (GRAPHIC) — 135KB
- tm242285d1_ex99-2img002.jpg (GRAPHIC) — 407KB
- tm242285d1_ex99-2img003.jpg (GRAPHIC) — 235KB
- tm242285d1_ex99-2img004.jpg (GRAPHIC) — 157KB
- tm242285d1_ex99-2img005.jpg (GRAPHIC) — 111KB
- tm242285d1_ex99-2img006.jpg (GRAPHIC) — 81KB
- tm242285d1_ex99-2img007.jpg (GRAPHIC) — 166KB
- tm242285d1_ex99-2img008.jpg (GRAPHIC) — 97KB
- tm242285d1_ex99-2img009.jpg (GRAPHIC) — 127KB
- tm242285d1_ex99-2img010.jpg (GRAPHIC) — 120KB
- tm242285d1_ex99-2img011.jpg (GRAPHIC) — 179KB
- tm242285d1_ex99-2img012.jpg (GRAPHIC) — 110KB
- tm242285d1_ex99-2img013.jpg (GRAPHIC) — 123KB
- tm242285d1_ex99-2img014.jpg (GRAPHIC) — 136KB
- tm242285d1_ex99-2img015.jpg (GRAPHIC) — 118KB
- tm242285d1_ex99-2img016.jpg (GRAPHIC) — 81KB
- tm242285d1_ex99-2img017.jpg (GRAPHIC) — 125KB
- tm242285d1_ex99-2img018.jpg (GRAPHIC) — 75KB
- tm242285d1_ex99-2img019.jpg (GRAPHIC) — 223KB
- tm242285d1_ex99-2img020.jpg (GRAPHIC) — 115KB
- tm242285d1_ex99-2img021.jpg (GRAPHIC) — 76KB
- 0001104659-24-002086.txt ( ) — 4423KB
- mrkr-20240108.xsd (EX-101.SCH) — 3KB
- mrkr-20240108_lab.xml (EX-101.LAB) — 33KB
- mrkr-20240108_pre.xml (EX-101.PRE) — 22KB
- tm242285d1_8k_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. As previously announced, the Marker Therapeutics, Inc. (the "Company") management team led by Chief Executive Officer, Juan Vera, plans to participate in the Biotech Showcase and present at the 19 th Annual Non-Dilutive Funding Summit held alongside the 42 nd Annual J.P. Morgan Healthcare Conference 2024 (J.P. Morgan Week). On January 8, 2024, the Company issued a press release announcing Clinical Program Updates and Pipeline Prioritization. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. In addition, on January 8, 2024, the Company updated its corporate presentation for use in meetings with investors, analysts and others during J.P. Morgan Week and thereafter, as well as in connection with the non-dilutive funding summit. The corporate presentation is available through the Company's website and a copy is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K. The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 and 99.2) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release, dated January 8, 2024. 99.2 Corporate Presentation, dated January 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Marker Therapeutics, Inc. Dated: January 8, 2024 By: /s/ Juan Vera Juan Vera President and Chief Executive Officer